These reductions reflect continued execution on our expense management initiatives.

May 8, 2025 / CFO / receipt, needs a key / Mark Hare, CFO | earnings call 2025-05-08 | transcript 0044bfd3-e3f8-4765-bda4-f9214af7433b | chars 9348-9431 | segment 9

Total operating expenses were $55.7 million in the fourth quarter of 2024, compared to $57.5 million in the fourth quarter of 2023. These reductions reflect continued execution on our expense management initiatives.

Feb 27, 2025 / CFO / receipt, needs a key / Mark Hare, CFO | earnings call 2025-02-27 | transcript 8a81fd12-fc16-4a72-989a-acb0d763078e | chars 13275-13490 | segment 13

We sold 6,459 lapoplasty procedure kits in the third quarter, a 13% increase compared to the same quarter last year, and was impacted by prioritized travel and vacations for our patient demographic, which led to lower than anticipated demand for our lapoplasty procedure in the quarter.

Nov 9, 2023 / CFO / receipt, needs a key / Mark Hare, CFO | earnings call 2023-11-09 | transcript bc3fd02a-7b91-47aa-8ce0-90c637b31a51 | chars 16083-16369 | segment 16